These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 27872093)

  • 1. A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzumab.
    Sijbrandi NJ; Merkul E; Muns JA; Waalboer DC; Adamzek K; Bolijn M; Montserrat V; Somsen GW; Haselberg R; Steverink PJ; Houthoff HJ; van Dongen GA
    Cancer Res; 2017 Jan; 77(2):257-267. PubMed ID: 27872093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody-Drug Conjugates: Taking Advantage of Dual Labeling with
    Muns JA; Montserrat V; Houthoff HJ; Codée-van der Schilden K; Zwaagstra O; Sijbrandi NJ; Merkul E; van Dongen GAMS
    J Nucl Med; 2018 Jul; 59(7):1146-1151. PubMed ID: 29496986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First platinum(II)-based metal-organic linker technology (Lx®) for a plug-and-play development of antibody-drug conjugates (ADCs).
    Merkul E; Sijbrandi NJ; Muns JA; Aydin I; Adamzek K; Houthoff HJ; Nijmeijer B; Van Dongen GAMS
    Expert Opin Drug Deliv; 2019 Aug; 16(8):783-793. PubMed ID: 31327255
    [No Abstract]   [Full Text] [Related]  

  • 5. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.
    Cilliers C; Menezes B; Nessler I; Linderman J; Thurber GM
    Cancer Res; 2018 Feb; 78(3):758-768. PubMed ID: 29217763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
    Beerli RR; Hell T; Merkel AS; Grawunder U
    PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of antibody-drug conjugates with high drug-to-antibody ratio using dimaleimide-DM1 as a linker- payload.
    Jeon JH; Woo Kim S; Kim YJ; Park JW; Eun Moon J; Beom Lee Y; Yu H; Lee GH; Jin SH; Jeong JH
    Bioorg Chem; 2024 Aug; 149():107504. PubMed ID: 38850783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling.
    Cohen R; Vugts DJ; Visser GW; Stigter-van Walsum M; Bolijn M; Spiga M; Lazzari P; Shankar S; Sani M; Zanda M; van Dongen GA
    Cancer Res; 2014 Oct; 74(20):5700-10. PubMed ID: 25145670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
    Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
    Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability.
    Ko MJ; Song D; Kim J; Kim JY; Eom J; Sung B; Son YG; Kim YM; Lee SH; You WK; Jung J
    MAbs; 2021; 13(1):1914885. PubMed ID: 33904380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
    Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
    MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.
    White JB; Fleming R; Masterson L; Ruddle BT; Zhong H; Fazenbaker C; Strout P; Rosenthal K; Reed M; Muniz-Medina V; Howard P; Dixit R; Wu H; Hinrichs MJ; Gao C; Dimasi N
    MAbs; 2019 Apr; 11(3):500-515. PubMed ID: 30835621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.
    Aubrey N; Allard-Vannier E; Martin C; Bryden F; Letast S; Colas C; Lakhrif Z; Collinet N; Dimier-Poisson I; Chourpa I; Viaud-Massuard MC; Joubert N
    Bioconjug Chem; 2018 Nov; 29(11):3516-3521. PubMed ID: 30352511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual intra- and extracellular release of monomethyl auristatin E from a neutrophil elastase-sensitive antibody-drug conjugate.
    Mohamed Amar IA; Huvelle S; Douez E; Letast S; Henrion S; Viaud-Massuard MC; Aubrey N; Allard-Vannier E; Joubert N; Denevault-Sabourin C
    Eur J Med Chem; 2022 Feb; 229():114063. PubMed ID: 34974337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of Hydrophilic Auristatin Derivatives for Use in Antibody Drug Conjugates.
    Mendelsohn BA; Barnscher SD; Snyder JT; An Z; Dodd JM; Dugal-Tessier J
    Bioconjug Chem; 2017 Feb; 28(2):371-381. PubMed ID: 28060485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.